Niels Van De Donk MD, PhD

Niels van de Donk is a professor in Hematology at the Amsterdam University Medical Center, where he was appointed as a full professor in February 2020. He specialized in hematology at the University Medical Center Utrecht. Following a fellowship at the Jerome Lipper Multiple Myeloma Center, and Dana-Farber Cancer Institute in Boston, he assumed his current post in Amsterdam.

Niels van de Donk’s special interest is the treatment of patients with multiple myeloma. He is the principal investigator of several investigator-initiated studies. Furthermore, he is involved in translational research towards finding new targets for therapy with a focus on immune therapy. He is also involved in the evaluation of new agents in preclinical studies, as well as in early (first-in-man) and more advanced clinical trials. This includes the investigation of antibodies, bispecific antibodies, antibody-drug conjugates, CAR T cells, and next-generation immunomodulatory drugs (IMiDs and CELMoDs). Another research interest is to obtain an increased understanding of the mode of action and mechanisms of resistance of immunotherapeutic agents through in vitro analyses combined with immune monitoring studies.

Van de Donk is the author or co-author of several books and many papers published in peer-reviewed journals. He is also secretary of the HOVON multiple myeloma working party and scientific secretary of the European Myeloma Network. He has been serving on the EHA Scientific Program Committee since 2018.